Healius (ASX:HLS) projects FY24 EBITDA at $345-350M

Healthcare company Healius anticipates recording FY24 underlying EBITDA of $345-350 million and underlying EBIT of $60-65 million.

Pathology volumes increased by 3.9% from January to May, offset by lower GP market fees amid inflationary pressures.

The company expects to exceed its FY24 pathology transformation savings target of $15 million.